Business Wire

H2SITE Launches Norwegian Subsidiary to Accelerate Ammonia-to-Power and Maritime Decarbonisation

21.1.2026 07:00:00 CET | Business Wire | Press Release

Share

H2SITE has launched H2SITE Norway AS, a new subsidiary based in Bergen, to enable the future of maritime hydrogen solutions. The company’s presence in Norway reflects its intention to work closer to the maritime and offshore industry and to support the practical deployment of hydrogen-based solutions for vessel decarbonisation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120617713/en/

H2SITE Ammonia Cracking Solution

H2SITE is a Spanish scale-up company headquartered in Bilbao, where the core of its technology is designed and manufactured. From its industrial facility in Loiu (Bizkaia), H2SITE produces thousands of palladium-alloy membranes each year, which are integrated into membrane reactor systems enabling efficient conversion of hydrogen carriers back into hydrogen. In the case of ammonia, H2SITE has developed cracking systems capable of delivering high-purity hydrogen that can be supplied directly to fuel cells or blend in engines. This capability is particularly relevant for maritime and offshore applications, where operational reliability, system integration and fuel logistics are critical.

Norway represents a highly relevant environment for this technology. The country combines a strong maritime heritage with clear climate ambitions and a pragmatic, goal-oriented approach to innovation and first-of-a-kind projects. Norway is already assessing the use of ammonia onboard vessels in commercial operations. With a local presence, H2SITE aims to work directly with Norwegian shipowners, shipyards and technology partners to adapt its systems to real vessel profiles and operating conditions.

The decision to invest now is driven by risk management. H2SITE believes that the commercial and regulatory risks of delaying decarbonisation now outweigh the risks associated with adopting new technologies. Ammonia, when used as an energy carrier and combined with efficient conversion systems, offers a credible route towards zero-emissions vessels and long-term compliance rather than short-term mitigation.

H2SITE Norway AS has been established at a stage where the technology is already validated, and the focus has moved to product implementation. Since 2023, H2SITE has built and operated ammonia crackers for more than 6,000 hours, including extended continuous operation in relevant environments. Maritime-focused projects such as H2Ocean and APOLO have addressed integration with fuel cells and engines. In parallel, H2SITE is building MW-scale systems and has reached the manufacturing capacity required to support early commercial projects.

Achieving zero-emissions vessels across multiple segments remains challenging. Vessel types such as RoRo, bulk carriers, platform supply vessels and tankers face technical and operational barriers. While ammonia-to-power 4-stroke engines are approaching commercial readiness, challenges remain at low loads, including ammonia slip and the need for pilot fuel. Onboard cracking allows shipowners to benefit from liquid ammonia storage and established logistics while producing hydrogen that enhances combustion and enables the use of fuel cells for high-efficiency auxiliary power. Hybrid solutions, as well as full fuel-cell propulsion, provide practical pathways towards ammonia-fuelled zero-emissions vessels. Regulatory developments reinforce this direction. While global frameworks such as IMO regulations continue to evolve, FuelEU Maritime and the EU Emissions Trading System are already shaping investment decisions and will progressively tighten over time.

H2SITE Norway is positioned as a platform for collaboration. The next step is pilot and demonstration projects that allow systems to be integrated and operated under realistic conditions. “The technology is proven; the priority now is implementation of the product and operational learning,” said Tomás Crespo, Maritime Business Development Manager at H2SITE Norway. “We are looking to work with Norwegian shipowners and shipyards that want to take a measured, forward-looking approach to decarbonisation.”

Looking ahead, the coming year will be about projects and execution deploying systems in real operating environments, gathering operational data and refining solutions in close cooperation with the Norwegian maritime industry. This strategic initiative highlights H2SITE’s dedication to addressing one of the key challenges in maritime decarbonisation: enabling efficient and economically viable onboard hydrogen production. By making hydrogen available at sea for both propulsion and auxiliary power systems, we are actively supporting the transition toward a cleaner and more competitive future for the shipping industry.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120617713/en/

Contacts

For more information:
Tomás Crespo, Maritime Business Development Manager at H2SITE Norway -
Tomas.crespo@h2site.com
Andrés Galnares, CEO of H2SITE - Andres.galnares@h2site.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye